



NEONATAL

# MENINGOCOCCAL VACCINE GROUP A, C, W135, Y (Nimenrix®)




This document should be read in conjunction with this [DISCLAIMER](#)

**Unrestricted:** Any prescriber may initiate treatment as per guideline

**For Aboriginal and Torres Strait Islander Infants ONLY**

<b>Presentation</b>	Nimenrix® powder and solvent for reconstitution.
<b>Classification</b>	Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine  Immunisation to prevent meningococcal disease caused by <i>Neisseria meningitidis</i>
<b>Indication</b>	<b>Prevention of meningococcal disease caused by <i>Neisseria meningitidis</i> for Aboriginal and Torres Strait Islander infants</b> <ul style="list-style-type: none"> <li>• 2 months of age, and;</li> <li>• 4 months of age, and;</li> <li>• 12 months of age.</li> </ul> <p><b>NOTE:</b> Parent/Guardian consent is to be obtained prior to administration of all vaccinations.</p>
<b>Dose</b>	<b>Intramuscular:</b> 0.5mL
<b>Monitoring</b>	Aboriginal and Torres Strait Islander receiving meningococcal ACWY immunisation are to have a full set of observations taken prior to immunisation and then continue full observations with feeds for 48 hours post immunisation.  Monitor temperature - Do not give during febrile illness or acute infection.
<b>Guidelines &amp; Resources</b>	<a href="#">Immunistations</a> <a href="#">West Australian Immunisation Schedule</a>

<b>Compatible Fluids</b>	Do not combine with any fluids or other vaccinations
<b>Preparation</b>	<p>Nimenrix® must be reconstituted by adding the entire contents of the pre-filled syringe of solvent to the vial containing powder.</p> <p>Shake well until the powder is completely dissolved.</p> <p>The reconstituted vaccine is a clear colourless solution.</p> <p>Do NOT use if solution is not clear and colourless</p> <p>Withdraw reconstituted contents into the syringe (0.5mL)</p>
<b>Administration</b>	<p><b>Intramuscular Injection ONLY</b></p> <p>Administer the entire reconstituted vial volume (0.5 mL) by intramuscular injection (IMI) to the anterolateral aspect of the thigh (slowly to reduce pain).</p> <p>Men ACWY Vaccine can be given at the same time as Infanrix Hexa® and combined DTP/Hib/IPV vaccine.</p>
<b>Adverse Reactions</b>	Pain and redness at injection site, fever, swelling, drowsiness
<b>Storage</b>	Refrigerate – do not freeze
<b>Notes</b>	<p>Men ACWY vaccines can be co-administered with other scheduled vaccines. If not co-administering; the Men ACWY vaccine should be given at least 4 weeks later. Intervals less than 4 weeks should be authorised by the neonatologist/microbiologist.</p> <p>There should be a minimum interval of 8 weeks between Men ACWY doses.</p> <p>Nimenrix® contains a conjugated tetanus toxoid as a carrier protein for the vaccine.</p>
<b>References</b>	<p>Australian Technical Advisory Group on Immunisation (ATAGI). The Australian immunisation handbook 10th edition [Internet]. Canberra: Australian Government Department of Health; 2018 [cited 2019 Apr 15]. Available from: <a href="http://www.immunise.health.gov.au">http://www.immunise.health.gov.au</a></p> <p>MIMS Australia. Nimenrix. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2019 Apr 15]. Available from: <a href="https://www.mimsonline.com.au">https://www.mimsonline.com.au</a></p>

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	October 2001	Version:	1.2
Last reviewed:	April 2019	Next review date:	April 2022
Endorsed by:	Neonatal Directorate Management Group	Date:	April 2019
Standards Applicable:	NSQHS Standards: 1  Governance 3  Infection Control 4  Medication Safety;		
<b>Printed or personally saved electronic copies of this document are considered uncontrolled.                      Access the current version from the WNHS website.</b>			

© Department of Health Western Australia 2018